Abstract
The usefulness of felbamate (FBM) levels in managing epilepsy patients has not been determined. The purpose of the present study was to determine if FBM levels obtained at routine office visits correlated with side effects reported by patients. We determined FBM levels by high-pressure liquid chromatography (HPLC) of 46 epilepsy patient plasma specimens (41 patients) and assessed medication toxicity and seizure frequency by a questionnaire. Thirty-six patients were treated with other antiepileptic drugs (AEDs); concomitant AED levels not in ranges believed to cause toxicity. FBM levels ranged from 9 to 134 microgram/ml, and were divided into three groups for analysis, resulting in low-range (9-36 microgram/ml), midrange (37-54 microgram/ml), and high-level (44-134 microgram/ml) groups. Anorexia and complaints of severe side effects were reported significantly more often in the high-level group as compared with the low- and midrange groups. Significantly more patients in the high-level group (10/13) reported decreased seizure frequency, as compared with 12 of 30 patients in the low- and midrange groups combined. FBM levels correlated linearly with doses overall, but most closely in FBM monotherapy patients.
References
Sep 1, 1992·Annals of Neurology·R SachdeoS Sachdeo
May 1, 1991·Epilepsia·M L WagnerI E Leppik
Nov 1, 1991·Neurology·I E LeppikJ J Cereghino
May 1, 1991·Epilepsia·W H TheodoreM Balish
Nov 22, 1990·The New England Journal of Medicine·M L Scheuer, T A Pedley
Jan 1, 1988·Epilepsia·I E Leppik
Nov 1, 1985·Epilepsia·A J WilenskyR H Levy
Feb 1, 1994·Therapeutic Drug Monitoring·L A RomanyshynR D Sofia
Jan 7, 1993·The New England Journal of Medicine·UNKNOWN Felbamate Study Group in Lennox-Gastaut Syndrome
Apr 1, 1993·Neurology·E FaughtR Kuzniecky
Apr 1, 1993·Neurology·B BourgeoisA Rosenberg
Citations
Oct 8, 1998·Life Sciences·R Corradetti, A M Pugliese
Feb 2, 2002·Epilepsy Research·Zaheed HusainEdmond J Yunis
Apr 21, 1999·Epilepsy Research·H SiegelW H Theodore
Jul 15, 2000·Clinical Neuropharmacology·B F Bourgeois
Apr 10, 2008·Epilepsia·Philip N PatsalosEmilio Perucca
Apr 5, 2000·Clinical Pharmacokinetics·E Perucca
Oct 20, 2006·Clinical Pharmacokinetics·Svein I Johannessen, Torbjörn Tomson
Sep 19, 2006·Drugs·Svein I Johannessen, Elinor Ben-Menachem
Mar 3, 2010·CNS Drugs·Dean P Sarco, Blaise F D Bourgeois
Jan 24, 2002·Therapeutic Drug Monitoring·Houda HachadRene H Levy
Dec 22, 1999·Therapeutic Drug Monitoring·M ContinA A Baruzzi
Jun 1, 1997·Therapeutic Drug Monitoring·C E Behnke, M N Reddy
May 27, 2003·Therapeutic Drug Monitoring·Svein I JohannessenPhilip N Patsalos
Feb 24, 2001·Journal of Toxicology. Clinical Toxicology·D S RengstorffT J Meredith
Dec 25, 2012·The Journal of Urology·Anas I GhoushehCharles T Durkee
Mar 9, 2010·Thérapie·Olivier TributUNKNOWN le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Aug 2, 2005·European Journal of Pharmacology·Patrick K HarrisonJohn E H Tattersall
Oct 22, 2016·Drugs in R&D·Shery Jacob, Anroop B Nair
Mar 11, 2009·Human & Experimental Toxicology·A CzubakA Matschay
Dec 7, 2000·Journal of Child Neurology·S R Snodgrass, B R Parks
Apr 16, 2002·Journal of Child Neurology·Raj D Sheth
Mar 10, 2018·Current Neuropharmacology·Irene Aicua-RapunJan Novy